Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, reported encouraging interim results from its Phase 2a clinical trial of HT-001, an investigational topical treatment for skin toxicities induced by Epidermal Growth Factor Receptor Inhibitors or EGFRi in cancer patients.
The Phase 2a trial, dubbed CLEER-001, consists of two parts - Part 1 and Part 2.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com